Mookherjee S, Ashutosh K, Dunsky M, Hill N, Vardan S, Smulyan H, Warner R
Department of Medicine, VA Medical Center, Syracuse, NY 13210.
Clin Pharmacol Ther. 1988 Sep;44(3):289-96. doi: 10.1038/clpt.1988.152.
After 20 mg sublingual nifedipine in 12 men with clinical stable chronic cor pulmonale the mean arterial pressure and systemic vascular resistance fell, cardiac index rose, and mean pulmonary arterial (Ppa) and wedge (Ppaw) pressures, right atrial pressure, and PaO2 remained unchanged. After 20 mg orally every 6 hours for 24 hours in 11 patients, the mean arterial pressure fell further, systemic vascular resistance remained low, and the cardiac index returned to baseline, whereas the Ppa and Ppaw decreased, but the pulmonary vascular driving pressure (Ppa-Ppaw), right atrial pressure, PaO2, and spirometry and ejection fractions remained unchanged. Of eight patients receiving maintenance therapy four developed untoward side effects in 1 to 3 weeks and one was noncompliant. The remaining three patients evaluated at 6 weeks failed to improve and had unchanged resting hemodynamics. Thus in the absence of a potentially reversible hypoxic pulmonary hypertension, nifedipine may not improve pulmonary arterial pressure and cardiac function in clinically stable patients with cor pulmonale.
对12名临床稳定的慢性肺心病男性患者舌下含服20毫克硝苯地平后,平均动脉压和全身血管阻力下降,心脏指数上升,而平均肺动脉压(Ppa)、楔压(Ppaw)、右心房压和PaO2保持不变。对11名患者每6小时口服20毫克,持续24小时后,平均动脉压进一步下降,全身血管阻力仍较低,心脏指数恢复至基线水平,而Ppa和Ppaw降低,但肺血管驱动压(Ppa - Ppaw)、右心房压、PaO2以及肺活量测定和射血分数保持不变。在接受维持治疗的8名患者中,4名在1至3周内出现了不良反应,1名不依从治疗。其余3名在6周时接受评估的患者病情未改善,静息血流动力学也未改变。因此,在不存在潜在可逆性低氧性肺动脉高压的情况下,硝苯地平可能无法改善临床稳定的肺心病患者的肺动脉压和心功能。